Advanced Malignancy - Pipeline Review, H2 2012

Description: Advanced Malignancy – Pipeline Review, H2 2012

Summary

Global Markets Direct's, 'Advanced Malignancy - Pipeline Review, H2 2012', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Advanced Malignancy, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Advanced Malignancy. Advanced Malignancy - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Advanced Malignancy.
- A review of the Advanced Malignancy products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Advanced Malignancy pipeline on the basis of route of administration and molecule type.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Advanced Malignancy.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Advanced Malignancy pipeline depth and focus of indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Contents:

2
List of Tables 9
List of Figures 15
Introduction 17
REPORT COVERAGE 17
Advanced Malignancy Overview 18
Therapeutics Development 19
An Overview of Pipeline Products for Gastric Cancer 19
Gastric Cancer Therapeutics under Development by Companies 21
Gastric Cancer Therapeutics under Investigation by Universities/Institutes 38
Late Stage Products 53
Comparative Analysis 53
Mid Clinical Stage Products 54
Comparative Analysis 54
Early Clinical Stage Products 55
Comparative Analysis 55
Discovery and Pre-Clinical Stage Products 56
Comparative Analysis 56
Advanced Malignancy Therapeutics – Products under Development by Companies 57
Advanced Malignancy Therapeutics – Products under Investigation by Universities/Institutes 105
Companies Involved in Gastric Cancer Therapeutics Development 151
Bristol-Myers Squibb Company 151
Genzyme Corporation 152
Baxter International Inc. 153
Boehringer Ingelheim GmbH 154
F. Hoffmann-La Roche Ltd. 155
Kyowa Hakko Kirin Co., Ltd. 156
Abbott Laboratories 157
Biogen Idec Inc. 158
Amgen Inc. 159
Sanofi-Aventis 160
Adherex Technologies Inc. 161
AstraZeneca PLC 162
Eli Lilly and Company 163
GlaxoSmithKline plc 164
Seattle Genetics, Inc. 165
Tekmira Pharmaceuticals Corp. 166
Genentech, Inc. 167
MedImmune LLC 168
Isis Pharmaceuticals, Inc. 169
Daichi Sankyo Company, Ltd 170
Merck & Co., Inc. 171
Esperance Pharmaceuticals, Inc. 304
Etubics Corporation 305
Immunocore Limited. 306
BIND Biosciences, Inc. 307
Tragara Pharmaceuticals, Inc. 308
Drais Pharmaceuticals, Inc. 309
Cellceutix Corporation 310
PharmaMar, S.A. 311
VentiRx Pharmaceuticals, Inc. 312
AB Science 313
Kinex Pharmaceuticals, LLC 314
Adamis Pharmaceuticals Corporation 315
Tigris Pharmaceuticals, Inc. 316
Celtic Biotech, Ltd. 317
Cylene Pharmaceuticals, Inc. 318
Genelux Corporation 319
Biothera 320
Nereus Pharmaceuticals, Inc. 321
Viventia Biotechnologies Inc. 322
AVEO Pharmaceuticals, Inc. 323
TRACON Pharmaceuticals, Inc. 324
Pierre Fabre Medicament 325
Perseus Proteomics, Inc. 326
Clovis Oncology, Inc. 327
Amplimmune, Inc. 328
PharmAbcine, Inc. 329
Pathway Therapeutics Limited 330
PNP Therapeutics, Inc. 331
Zenyaku Kogyo Co., Ltd. 332
BioProspecting NB, Inc. 333
Aragon Pharmaceuticals, Inc. 334
RECEPTA Biopharma S.A. 335
Vakzine Projekt Management GmbH 336
NuCana BioMed Limited 337
Polaris Group 338
Eurofarma 339
XBiotech USA, Inc. 340
DEKK-TEC, Inc. 341
Agennix AG 342
Regunol Inc. 343
Acacia Pharma Ltd. 344
Gradalis Inc. 345
SentoClone AB 346
Oncozyme Pharma Inc. 347
Biotech Pharmaceuticals Co., Ltd. 348
Gastric Cancer – Therapeutics Assessment 349
Assessment by Monotherapy Products 349
Assessment by Combination Products 350
Assessment by Route of Administration 351
Assessment by Molecule Type 353
Drug Profiles 355
perifosine - Drug Profile 355
motesanib diphosphate - Drug Profile 358
brivanib alaninate - Drug Profile 360
trastuzumab - Drug Profile 362
linifanib - Drug Profile 365
vismodegib - Drug Profile 367
brentuximab vedotin - Drug Profile 370
fulvestrant - Drug Profile 373
yttrium Radiotherapy - Drug Profile 375
canfosfamide hydrochloride - Drug Profile 377
YN-968D1 - Drug Profile 379
AGS-003 - Drug Profile 381
Docetaxel + S-1 - Drug Profile 383
Perifosine + Xeloda - Drug Profile 384
Docetaxel + Prednisone + Atrasentan - Drug Profile 386
trabectedin - Drug Profile 388
Fulvestrant + Lapatinib - Drug Profile 390
Oxaliplatin + Capecitabine + Radiation Therapy - Drug Profile 391
cisplatin - Drug Profile 393
Torisel + Bevacizumab - Drug Profile 394
memantine - Drug Profile 397
Panitumumab - Drug Profile 398
bevacizumab + pemetrexed + cisplatin - Drug Profile 399
Capecitabine + Gemcitabine - Drug Profile 400
Gemcitabine + Capecitabine + Radiation Therapy - Drug Profile 401
Androgen suppression + Zoledronate - Drug Profile 403
Docetaxel + Cisplatin + Cetuximab + Radiation Therapy - Drug Profile 404
Docetaxel + Cisplatin + Hydroxyurea + 5-Fluorouracil - Drug Profile 406
Capecitabine + Bevacizumab - Drug Profile 409
Cetuximab + Radiation Therapy - Drug Profile 410
TV-1011 + Docetaxel - Drug Profile 411
Sunitinib + Erlotinib - Drug Profile 413
AMG 706 + Paclitaxel + Carboplatin - Drug Profile 414
Faslodex + Anthracyclines - Drug Profile 416
Zactima + Taxotere - Drug Profile 417
Oxaliplatin + Leucovorin + Fluorouracil + Irinotecan - Drug Profile 419
Aflibercept + Docetaxel - Drug Profile 421
Larotaxel + Cisplatin - Drug Profile 423
Vinflunine + Capecitabine - Drug Profile 425
CCI-779 + Interferon Alfa - Drug Profile 426
afatinib - Drug Profile 427
Zactima + Alimta - Drug Profile 429
Capecitabine + Oxaliplatin + Radiation Therapy - Drug Profile 431
Taxotere + Cisplatin + Fluorouracil - Drug Profile 433
XRP6976 + Oxaliplatin + S-1 - Drug Profile 435
List of Tables

Number of Products Under Development for Gastric Cancer, H2 2012 26
Products under Development for Gastric Cancer – Comparative Analysis, H2 2012 27
Number of Products under Development by Companies, H2 2012 29
Number of Products under Development by Companies, H2 2012 (Contd..) 30
Number of Products under Development by Companies, H2 2012 (Contd..2) 31
Number of Products under Development by Companies, H2 2012 (Contd..3) 32
Number of Products under Development by Companies, H2 2012 (Contd..4) 33
Number of Products under Development by Companies, H2 2012 (Contd..5) 34
Number of Products under Development by Companies, H2 2012 (Contd..6) 35
Number of Products under Development by Companies, H2 2012 (Contd..7) 36
Number of Products under Development by Companies, H2 2012 (Contd..8) 37
Number of Products under Development by Companies, H2 2012 (Contd..9) 38
Number of Products under Development by Companies, H2 2012 (Contd..10) 39
Number of Products under Development by Companies, H2 2012 (Contd..11) 40
Number of Products under Development by Companies, H2 2012 (Contd..12) 41
Number of Products under Development by Companies, H2 2012 (Contd..13) 42
Number of Products under Development by Companies, H2 2012 (Contd..14) 43
Number of Products under Development by Companies, H2 2012 (Contd..15) 44
Number of Products under Investigation by Universities/Institutes, H2 2012 46
Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..) 47
Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..2) 48
Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..3) 49
Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..4) 50
Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..5) 51
Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..6) 52
Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..7) 53
Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..8) 54
Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..9) 55
Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..10) 56
Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..11) 57
Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..12) 58
Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..13) 59
Comparative Analysis by Late Stage Development, H2 2012 60
Comparative Analysis by Mid Clinical Stage Development, H2 2012 61
Comparative Analysis by Early Clinical Stage Development, H2 2012 62
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H2 2012 63
Products under Development by Companies, H2 2012 64
Products under Development by Companies, H2 2012 (Contd..1) 65
Products under Development by Companies, H2 2012 (Contd..2) 66
Products under Development by Companies, H2 2012 (Contd..3) 67
Products under Development by Companies, H2 2012 (Contd..4) 68
Products under Development by Companies, H2 2012 (Contd..5) 69
Products under Development by Companies, H2 2012 (Contd..6) 70
Products under Development by Companies, H2 2012 (Contd..7) 71
Products under Development by Companies, H2 2012 (Contd..8) 72
Products under Development by Companies, H2 2012 (Contd..9) 73
Products under Development by Companies, H2 2012 (Contd..10) 74
Products under Development by Companies, H2 2012 (Contd..11) 75
Products under Development by Companies, H2 2012 (Contd..12) 76
Products under Development by Companies, H2 2012 (Contd..13) 77
Products under Development by Companies, H2 2012 (Contd..14) 78
Products under Development by Companies, H2 2012 (Contd..15) 79
Products under Investigation by Universities/Institutes, H2 2012 (Contd..31) 143
Products under Investigation by Universities/Institutes, H2 2012 (Contd..32) 144
Products under Investigation by Universities/Institutes, H2 2012 (Contd..33) 145
Products under Investigation by Universities/Institutes, H2 2012 (Contd..34) 146
Products under Investigation by Universities/Institutes, H2 2012 (Contd..35) 147
Products under Investigation by Universities/Institutes, H2 2012 (Contd..36) 148
Products under Investigation by Universities/Institutes, H2 2012 (Contd..37) 149
Products under Investigation by Universities/Institutes, H2 2012 (Contd..38) 150
Products under Investigation by Universities/Institutes, H2 2012 (Contd..39) 151
Products under Investigation by Universities/Institutes, H2 2012 (Contd..40) 152
Products under Investigation by Universities/Institutes, H2 2012 (Contd..41) 153
Products under Investigation by Universities/Institutes, H2 2012 (Contd..42) 154
Products under Investigation by Universities/Institutes, H2 2012 (Contd..43) 155
Products under Investigation by Universities/Institutes, H2 2012 (Contd..44) 156
Products under Investigation by Universities/Institutes, H2 2012 (Contd..45) 157
Bristol-Myers Squibb Company, H2 2012 158
F. Hoffmann-La Roche Ltd., H2 2012 162
Abbott Laboratories, H2 2012 164
Amgen Inc., H2 2012 166
Sanofi-Aventis, H2 2012 167
AstraZeneca PLC, H2 2012 169
Eli Lilly and Company, H2 2012 170
GlaxoSmithKline plc, H2 2012 171
Tekmira Pharmaceuticals Corp., H2 2012 173
AbGenomics International, Inc., H2 2012 179
YM BioSciences Inc., H2 2012 184
Novartis AG, H2 2012 190
Astellas Pharma Inc., H2 2012 193
Eisai Co., Ltd., H2 2012 197
Pfizer Inc., H2 2012 202
Taiho Pharmaceutical Co., Ltd., H2 2012 205
Yakult Honsha Co., Ltd., H2 2012 207
Exelixis, Inc., H2 2012 211
Celgene Corporation, H2 2012 213
Merck KGaA, H2 2012 219
IMMUNOMEDICS, INC, H2 2012 227
Curis, Inc., H2 2012 241
ARQUELE, INC, H2 2012 244
ADVENTRX Pharmaceuticals, H2 2012 245
OncoTherapy Science, Inc., H2 2012 258
Jiangsu Hengrui Medicine Co., Ltd., H2 2012 259
NanoCarrier Co., Ltd., H2 2012 262
Rexahn Pharmaceuticals, Inc., H2 2012 263

List of Figures
Number of Products under Development for Gastric Cancer, H2 2012 26
Products under Development for Gastric Cancer – Comparative Analysis, H2 2012 27
Products under Development by Companies, H2 2012 28
Products under Investigation by Universities/Institutes, H2 2012 45
Late Stage Products, H2 2012 60
Mid Clinical Stage Products, H2 2012 61
Early Clinical Stage Products, H2 2012 62
Discovery and Pre-Clinical Stage Products, H2 2012 63
Assessment by Monotherapy Products, H2 2012 356
Assessment by Combination Products, H2 2012 357
Assessment by Route of Administration, H2 2012 358
Assessment by Stage and Route of Administration, H2 2012 359
Assessment by Molecule Type, H2 2012 360
Assessment by Stage and Molecule Type, H2 2012 361

Order by Fax - using the form below

Order by Post - print the order form below and send to

Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.
Fax Order Form
To place an order via fax simply print this form, fill in the information below and fax the completed form to 646-607-1907 (from USA) or +353-1-481-1716 (from Rest of World). If you have any questions please visit http://www.researchandmarkets.com/contact/

Order Information
Please verify that the product information is correct and select the format(s) you require.

<table>
<thead>
<tr>
<th>Product Name:</th>
<th>Advanced Malignancy - Pipeline Review, H2 2012</th>
</tr>
</thead>
<tbody>
<tr>
<td>Web Address:</td>
<td><a href="http://www.researchandmarkets.com/reports/2335114/">http://www.researchandmarkets.com/reports/2335114/</a></td>
</tr>
<tr>
<td>Office Code:</td>
<td>SCD27F6G</td>
</tr>
</tbody>
</table>

Product Formats
Please select the product formats and quantity you require:

<table>
<thead>
<tr>
<th>Quantity</th>
<th>Electronic (PDF) - Single User:</th>
<th>USD 2500</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Electronic (PDF) - Site License:</td>
<td>USD 5000</td>
</tr>
<tr>
<td></td>
<td>Electronic (PDF) - Enterprisewide:</td>
<td>USD 7500</td>
</tr>
</tbody>
</table>

Contact Information
Please enter all the information below in BLOCK CAPITALS

<table>
<thead>
<tr>
<th>Title:</th>
<th>Mr ☐</th>
<th>Mrs ☐</th>
<th>Dr ☐</th>
<th>Miss ☐</th>
<th>Ms ☐</th>
<th>Prof ☐</th>
</tr>
</thead>
<tbody>
<tr>
<td>First Name:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Last Name:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Email Address:</td>
<td>*</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Job Title:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Organisation:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Address:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>City:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Postal / Zip Code:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Country:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Phone Number:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Fax Number:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

* Please refrain from using free email accounts when ordering (e.g. Yahoo, Hotmail, AOL)
Payment Information

Please indicate the payment method you would like to use by selecting the appropriate box.

☐ Pay by credit card: You will receive an email with a link to a secure webpage to enter your credit card details.

☐ Pay by check: Please post the check, accompanied by this form, to:
Research and Markets,
Guinness Center,
Taylors Lane,
Dublin 8,
Ireland.

☐ Pay by wire transfer: Please transfer funds to:
Account number 833 130 83
Sort code 98-53-30
Swift code ULSBIE2D
IBAN number IE78ULSB98533083313083
Bank Address Ulster Bank,
27-35 Main Street,
Blackrock,
Co. Dublin,
Ireland.

If you have a Marketing Code please enter it below:
Marketing Code: _______________________

Please note that by ordering from Research and Markets you are agreeing to our Terms and Conditions at http://www.researchandmarkets.com/info/terms.asp

Please fax this form to:
(646) 607-1907 or (646) 964-6609 - From USA
+353-1-481-1716 or +353-1-653-1571 - From Rest of World